FABP4 is secreted from adipocytes by adenyl cyclase-PKA- and guanylyl cyclase-PKG-dependent lipolytic mechanisms

Obesity

Volumn 23, Issue 2, 2015, Pages 359-367

  Mita, Tomohiro ^a   Furuhashi, Masato ^a   Hiramitsu, Shinya ^b   Ishii, Junnichi ^c   Hoshina, Kyoko ^a   Ishimura, Shutaro ^a   Fuseya, Takahiro ^a   Watanabe, Yuki ^a   Tanaka, Marenao ^a   Ohno, Kohei ^a   Akasaka, Hiroshi ^a   Ohnishi, Hirofumi ^a   Yoshida, Hideaki ^a   Saitoh, Shigeyuki ^a,d   Shimamoto, Kazuaki ^d   Miura, Tetsuji ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Hiramitsu Heart Clinic Nagoya   (Japan)

^c FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ADENYLATE CYCLASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCLADESINE; CALCIUM CHANNEL BLOCKING AGENT; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID BINDING PROTEIN 4; FORSKOLIN; GLUCOSE; GUANYLATE CYCLASE; GUANYLATE CYCLASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ISOPRENALINE; KT 5823; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PALMITIC ACID; FABP4 PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN; GLUCOSE BLOOD LEVEL;

3T3 CELL LINE; ADIPOCYTE; ADULT; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; FAT INTAKE; FATTY ACID BINDING PROTEIN 4 BLOOD LEVEL; FEMALE; HUMAN; LIPOLYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; POSTPRANDIAL STATE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; AGED; ANALYSIS; ANIMAL; BLOOD; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; LIPID DIET; LIPID METABOLISM; METABOLISM; SECRETION (PROCESS);

3T3-L1 CELLS; ADENYLATE CYCLASE; ADIPOCYTES; ADULT; AGED; ANIMALS; BLOOD GLUCOSE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLIC GMP-DEPENDENT PROTEIN KINASES; DIET, HIGH-FAT; FATTY ACID-BINDING PROTEINS; FEMALE; GLUCOSE TOLERANCE TEST; GUANYLATE CYCLASE; HUMANS; INSULIN; LIPID METABOLISM; LIPOLYSIS; MALE; MICE; MIDDLE AGED;

EID: 84922725790     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20954     Document Type: Article

References (30)

1. Furuhashi M, Hotamisligil GS,. Fatty acid-binding proteins: Role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 2008; 7: 489-503.
2. Furuhashi M, Ishimura S, Ota H, Miura T,. Lipid chaperones and metabolic inflammation. Int J Inflam 2011; 2011: 642612.
3. Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM,. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996; 274: 1377-1379.
4. Makowski L, Boord JB, Maeda K, et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 2001; 7: 699-705.
5. Furuhashi M, Fucho R, Gorgun CZ, Tuncman G, Cao H, Hotamisligil GS,. Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Invest 2008; 118: 2640-2650.
6. Boord JB, Maeda K, Makowski L, et al. Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation 2004; 110: 1492-1498.
7. Furuhashi M, Tuncman G, Gorgun CZ, et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007; 447: 959-965.
8. Xu A, Wang Y, Xu JY, et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006; 52: 405-413.
9. Cao H, Sekiya M, Ertunc ME, et al. Adipocyte lipid chaperone AP2 is a secreted adipokine regulating hepatic glucose production. Cell Metab 2013; 17: 768-778.
10. Kralisch S, Ebert T, Lossner U, Jessnitzer B, Stumvoll M, Fasshauer M,. Adipocyte fatty acid-binding protein is released from adipocytes by a non-conventional mechanism. Int J Obes 2014; 38: 1251-1254.
11. Schlottmann I, Ehrhart-Bornstein M, Wabitsch M, Bornstein SR, Lamounier-Zepter V,. Calcium-dependent release of adipocyte fatty acid binding protein from human adipocytes. Int J Obes 2014; 38: 1221-1227.
12. Lamounier-Zepter V, Look C, Alvarez J, et al. Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: A new link between obesity and heart disease. Circ Res 2009; 105: 326-334.
13. Xu A, Tso AW, Cheung BM, et al. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: A 5-year prospective study. Circulation 2007; 115: 1537-1543.
14. Tso AW, Xu A, Sham PC, et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: A 10-year prospective study in a Chinese cohort. Diabetes Care 2007; 30: 2667-2672.
15. von Eynatten M, Breitling LP, Roos M, Baumann M, Rothenbacher D, Brenner H,. Circulating adipocyte fatty acid-binding protein levels and cardiovascular morbidity and mortality in patients with coronary heart disease: A 10-year prospective study. Arterioscler Thromb Vasc Biol 2012; 32: 2327-2335.
16. Ota H, Furuhashi M, Ishimura S, et al. Elevation of fatty acid-binding protein 4 is predisposed by family history of hypertension and contributes to blood pressure elevation. Am J Hypertens 2012; 25: 1124-1130.
17. Ishimura S, Furuhashi M, Watanabe Y, et al. Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general population. PLoS ONE 2013; 8: e81318.
18. Furuhashi M, Ishimura S, Ota H, et al. Serum fatty acid-binding protein 4 is a predictor of cardiovascular events in end-stage renal disease. PLoS ONE 2011; 6: e27356.
19. Fuseya T, Furuhashi M, Yuda S, et al. Elevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population. Cardiovasc Diabetol 2014; 13: 126.
20. Hiramitsu S, Miyagishima K, Ishii J, et al. Effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load. J Cardiol 2012; 60: 395-400.
21. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
22. Stich V, Berlan M,. Physiological regulation of NEFA availability: Lipolysis pathway. Proc Nutr Soc 2004; 63: 369-374.
23. Moro C, Lafontan M,. Natriuretic peptides and cGMP signaling control of energy homeostasis. Am J Physiol Heart Circ Physiol 2013; 304: H358-368.
24. Shen WJ, Sridhar K, Bernlohr DA, Kraemer FB,. Interaction of rat hormone-sensitive lipase with adipocyte lipid-binding protein. Proc Natl Acad Sci U S A 1999; 96: 5528-5532.
25. Scheja L, Makowski L, Uysal KT, et al. Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice. Diabetes 1999; 48: 1987-1994.
26. Coe NR, Simpson MA, Bernlohr DA,. Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels. J Lipid Res 1999; 40: 967-972.
27. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM,. mPPAR gamma 2: Tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994; 8: 1224-1234.
28. Nickel W, Rabouille C,. Mechanisms of regulated unconventional protein secretion. Nat Rev Mol Cell Biol 2009; 10: 148-155.
29. Karpisek M, Stejskal D, Kotolova H, et al. Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia. Eur J Clin Invest 2007; 37: 637-642.
30. Miyoshi T, Doi M, Hirohata S, et al. Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients. Heart Vessels 2011; 26: 408-413.